Clinical trial
Open-Label, Single-Center, Single-Arm Phase 2 Futility Trial Evaluating the Use of Oral Indapamide for Reducing Pprogression of Disability in People With Primary and Secondary Progressive Multiple Sclerosis (MS)
NCT07765212 is registered in ClinicalTrials.gov with Eva M.M. Strijbis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-Label, Single-Center, Single-Arm Phase 2 Futility Trial Evaluating the Use of Oral Indapamide for Reducing Pprogression of Disability in People With Primary and Secondary Progressive Multiple Sclerosis (MS)
- Lead sponsor
- Eva M.M. Strijbis
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- September 30, 2028
- Enrollment
- 75 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.